I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

MollyFerguson/STATIwaswrongaboutGeron.Foryears,I’vebelieved—anddeclaredpublicly—thatGeron’sefforttod 6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid




leisure time

author：entertainment    Page View：8767
Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC.
Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

advertisement

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Orchard's therapy for neuron disease in children wins FDA approval
Next article： Affirmative action in medical school literally saved lives